Announced
Completed
Philogen completed the merger with Palio Ordinarie in a $596m deal.
Synopsis
Philogen, a biotech company that develops biotech products for the imaging and therapy of life, completed the merger with Palio Ordinarie in a $596m deal. This merger made it possible to dissolve the vehicle Palio Ordinarie, contributing towards the generation of a free float equal to 17% for the listing process.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.